Cargando…

Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome

This study aimed to investigate the predictive value of liver metastases (LM) in patients with various advanced cancers received immune-checkpoint inhibitors (ICIs). First, clinical and survival data from a published cohort of 1,661 patients who received ICIs therapy were downloaded and analyzed. Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Juan, Ren, Aiqun, Zheng, Liang, Zheng, En-Dian, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264582/
https://www.ncbi.nlm.nih.gov/pubmed/34248939
http://dx.doi.org/10.3389/fimmu.2021.651086
_version_ 1783719589075484672
author Chen, Xiao-Juan
Ren, Aiqun
Zheng, Liang
Zheng, En-Dian
Jiang, Tao
author_facet Chen, Xiao-Juan
Ren, Aiqun
Zheng, Liang
Zheng, En-Dian
Jiang, Tao
author_sort Chen, Xiao-Juan
collection PubMed
description This study aimed to investigate the predictive value of liver metastases (LM) in patients with various advanced cancers received immune-checkpoint inhibitors (ICIs). First, clinical and survival data from a published cohort of 1,661 patients who received ICIs therapy were downloaded and analyzed. Second, a retrospective review of 182 patients with advanced non-small-cell lung cancer (NSCLC) who received PD-1/PD-L1 monotherapy was identified. Third, a meta-analysis of published trials was performed to explore the impact of LM on the efficacy of anti-PD-1/PD-L1 based therapy in advanced lung cancers. Pan-cancer analysis revealed that patients with LM had significantly shorter overall survival (OS) than those without LM (10 vs. 20 months; P < 0.0001). Subgroup analysis showed that the presence of LM was associated with markedly shorter OS than those without LM in ICI monotherapy group (P < 0.0001), but it did not reach the statistical significance in ICI-based combination therapy (P = 0.0815). In NSCLC, the presence of LM was associated with significantly inferior treatment outcomes in both pan-cancer and real-world cohort. Interestingly, ICI-based monotherapy and combination therapy could simultaneously prolong progression-free survival (PFS) and OS than chemotherapy in patients without LM. However, ICI-based monotherapy could not prolong PFS than chemotherapy in patients with LM while ICI-based combination therapy could dramatically prolong both PFS and OS. Together, these findings suggested that the presence of LM was the negative predictive factor in cancer patients received ICIs monotherapy, especially in NSCLC. ICI-based combination therapy might overcome the intrinsic resistance of LM to ICIs while the optimal combinatorial strategies remain under further investigation.
format Online
Article
Text
id pubmed-8264582
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82645822021-07-09 Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome Chen, Xiao-Juan Ren, Aiqun Zheng, Liang Zheng, En-Dian Jiang, Tao Front Immunol Immunology This study aimed to investigate the predictive value of liver metastases (LM) in patients with various advanced cancers received immune-checkpoint inhibitors (ICIs). First, clinical and survival data from a published cohort of 1,661 patients who received ICIs therapy were downloaded and analyzed. Second, a retrospective review of 182 patients with advanced non-small-cell lung cancer (NSCLC) who received PD-1/PD-L1 monotherapy was identified. Third, a meta-analysis of published trials was performed to explore the impact of LM on the efficacy of anti-PD-1/PD-L1 based therapy in advanced lung cancers. Pan-cancer analysis revealed that patients with LM had significantly shorter overall survival (OS) than those without LM (10 vs. 20 months; P < 0.0001). Subgroup analysis showed that the presence of LM was associated with markedly shorter OS than those without LM in ICI monotherapy group (P < 0.0001), but it did not reach the statistical significance in ICI-based combination therapy (P = 0.0815). In NSCLC, the presence of LM was associated with significantly inferior treatment outcomes in both pan-cancer and real-world cohort. Interestingly, ICI-based monotherapy and combination therapy could simultaneously prolong progression-free survival (PFS) and OS than chemotherapy in patients without LM. However, ICI-based monotherapy could not prolong PFS than chemotherapy in patients with LM while ICI-based combination therapy could dramatically prolong both PFS and OS. Together, these findings suggested that the presence of LM was the negative predictive factor in cancer patients received ICIs monotherapy, especially in NSCLC. ICI-based combination therapy might overcome the intrinsic resistance of LM to ICIs while the optimal combinatorial strategies remain under further investigation. Frontiers Media S.A. 2021-06-24 /pmc/articles/PMC8264582/ /pubmed/34248939 http://dx.doi.org/10.3389/fimmu.2021.651086 Text en Copyright © 2021 Chen, Ren, Zheng, Zheng and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Xiao-Juan
Ren, Aiqun
Zheng, Liang
Zheng, En-Dian
Jiang, Tao
Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title_full Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title_fullStr Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title_full_unstemmed Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title_short Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome
title_sort pan-cancer analysis identifies liver metastases as negative predictive factor for immune checkpoint inhibitors treatment outcome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264582/
https://www.ncbi.nlm.nih.gov/pubmed/34248939
http://dx.doi.org/10.3389/fimmu.2021.651086
work_keys_str_mv AT chenxiaojuan pancanceranalysisidentifieslivermetastasesasnegativepredictivefactorforimmunecheckpointinhibitorstreatmentoutcome
AT renaiqun pancanceranalysisidentifieslivermetastasesasnegativepredictivefactorforimmunecheckpointinhibitorstreatmentoutcome
AT zhengliang pancanceranalysisidentifieslivermetastasesasnegativepredictivefactorforimmunecheckpointinhibitorstreatmentoutcome
AT zhengendian pancanceranalysisidentifieslivermetastasesasnegativepredictivefactorforimmunecheckpointinhibitorstreatmentoutcome
AT jiangtao pancanceranalysisidentifieslivermetastasesasnegativepredictivefactorforimmunecheckpointinhibitorstreatmentoutcome